Canadian 3D bioprinting technology company Aspect Biosystems has announced its involvement in a $2.2 million project seeking to find new treatments for cancer. Starting this year, the company will be working with collaborators at two of the world’s largest pharmaceutical companies Merck and GSK, as well as McGill University’s Goodman Cancer Research Centre in Quebec. Tamer Mohamed, CEO of […]
328 Replies to “Aspect Biosystems 3D bioprinting selected for $2.2M cancer drug development project”
Comments are closed.